DRREDDY vs INDOCO: Stock Comparison

Dr Reddys Laboratories Ltd vs Indoco Remedies Limited

Live data: 22 July 2026, 2:52 PM IST • Source: NSE and company filings

Dr Reddys Laboratories Ltd is the larger company by market capitalisation. Dr Reddys Laboratories Ltd shows a higher ROE, a higher dividend yield and lower leverage, while Indoco Remedies Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Dr Reddys Laboratories Ltd and Indoco Remedies Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, DRREDDY is more favourable on 7 of 13 scored metrics and INDOCO on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DRREDDY is the larger company
₹98,815 Cr vs ₹2,160 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 24x
P/B Ratio
INDOCO has a lower P/B
2.41x vs 2.66x
EPS
DRREDDY has higher earnings per share
₹51.37 vs ₹-10.71
Dividend Yield
DRREDDY has a higher dividend yield
0.65% vs 0.08%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs -11.6%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -86.2%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
21.9% vs -11.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDRREDDYINDOCO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDRREDDYINDOCO
Live Price₹1,183₹233.99
Day Change-1.91%-4.82%
Volume20.37 L71,688
52-Week High₹1,414.9₹336
52-Week Low₹1,148.4₹162.19
Distance from 52W High-16.39%-30.36%

Valuation

MetricDRREDDYINDOCO
Market Cap₹98,815 Cr₹2,160 Cr
P/E Ratio24x-23.83x
P/B Ratio2.66x2.41x
EPS₹51.37₹-10.71
Book Value₹452.82₹111.55
Dividend Yield0.65%0.08%

Growth

MetricDRREDDYINDOCO
Revenue Growth (TTM YoY)-11.6%21.9%
EPS Growth (TTM YoY)-86.2%0%
Qtr Sales Growth-11.5%21.9%
Qtr Profit Growth-86.1%39%

Profitability & Leverage

MetricDRREDDYINDOCO
ROE11.2%-9.42%
ROCE13%0.93%
Net Margin12.76%-5.31%
Operating Margin19.2%7.68%
Debt to Equity0.2x1.16x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricDRREDDYINDOCO
Promoter Holding26.63% 0.01 pp58.86%
FII Holding33.08% 0.12 pp1.27% 0.33 pp
DII Holding30.72% 0.28 pp17.68% 0.47 pp
Public Holding9.33% 0.14 pp22.04% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Dr Reddys Laboratories Ltd and Indoco Remedies Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.